Publication

Featured Publications 

2026

Koh Y, Tengesdal IW, Jaiswal S. Clonal Hematopoiesis in Nonmalignant Disease: Functional Consequences of Mutated Immune Cells by Clonal Hematopoiesis in the Diseased Tissue. Annu Rev Pathol. 2026 Jan;21(1):19-36. doi: 10.1146/annurev-pathmechdis-111523-023442. Epub 2025 Sep 10. PMID: 40929507. 

2025

Lee, D., Koo, B., Kim, S. et al. Increased local DNA methylation disorder in AMLs with DNMT3A-destabilizing variants and its clinical implication. Nat Commun 16, 560 (2025). https://doi.org/10.1038/s41467-024-55691-z 

2024

Ahn HY, An HY, Ryu G, et al. Clonal haematopoiesis of indeterminate potential and atrial fibrillation: an east Asian cohort study. Eur Heart J. 2024;45(10):778-790 

Park C, Lee HS, Kang KW, Lee W, et al. Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial. Nat Comm. 2024;15(1):2776 

Yoon H, Dean LS, Jiyarom B, et al. Single-cell RNA sequencing reveals characteristics of myeloid cells in post-acute sequelae of SARS-CoV-2 patients with persistent respiratory symptoms. Front Immunol. 2024;8;14 

Lee G, Lee SM, Lee S, et al. Prediction of metabolites associated with somatic mutations in cancers by using genome-scale metabolic models and mutation data. Genome Biol. 2024;25(1):66 

Lee H, Song H, Choi SY, et al. Impact of clonal haematopoiesis on atherosclerotic cardiovascular disease according to low-density lipoprotein cholesterol levels in general population. Eur J Prev Cardiol. 2024;zwae055

Chun, C., Byun, J.M., Cha, M. et al. Profiling protein–protein interactions to predict the efficacy of B-cell-lymphoma-2-homology-3 mimetics for acute myeloid leukaemia. Nat. Biomed. Eng 8, 1379–1395 (2024). https://doi.org/10.1038/s41551-024-01241-3 

2023

Park W, Byun JM, Hong J, et al. Comparison of the effect of DLI according to cell sources in relapsed AML after allogeneic stem cell transplantation. Ann Hematol. 2023;ePub 

Park E, Lee C, Park J, et al. Mitigating the BFL-1 mediated antiapoptotic pathway in diffuse large B cell lymphoma by inhibiting HDACs. Leuk Lymphoma. 2023;64(1):205-216 

Shin J, Lee JY, Lee GW, et al. Phase II study of bortezomib, cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma. Br J Haematol. 2023;202(6):e54-e57 

Koh Y, Kim H, Joo SY, et al. Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma. J Transl Med. 2023;21(1):730 

Byun JM, Shin J, Kim SA, et al. A phase II study to evaluate the efficacy of bortezomib in combination with thalidomide in treatment-naive waldenstrom macroglobulinemia patients. Cancer Res Treat. 2023;ePub 

Yoon DH, Koh Y, Jung M, et al. Phase 1 study: Safety and efficacy of an ex vivo-expanded allogeneic natural killer cell (MG4101) with rituximab for relapsed/refractory B cell non-hodgkin lymphoma. Transplant Cell Ther. 2023;29(4):253 

Song S, Koh Y, Kim S, et al. Systematic analysis of Mendelian disease-associated gene variants reveals new classes of cancer-predisposing genes. Genome Med. 2023;15(1):107 

Yun JK, Kim S, An H, et al. Pre-operative clonal hematopoiesis is related to adverse outcome in lung cancer after adjuvant therapy. Genome Med. 2023;15(1):111

Kim DW, Byun JM, Lee JO, et al. Chemotherapy delivery time affects treatment outcomes of female patients with diffuse large B cell lymphoma. JCI Insight. 2023;8(2) 

Michael L. Wang et al. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol 41, 3988-3997(2023). DOI:10.1200/JCO.23.00562

Lee EJ, An HY, Lim J, Park KI, Choi SY, Jeong HY, Kang DW, Yang W, Kim JM, Ko SB, Lee SH, Yoon BW, Koh Y, Jung KH. Clonal Hematopoiesis and Acute Ischemic Stroke Outcomes. Ann Neurol. 2023 Nov;94(5):836-847. doi: 10.1002/ana.26754. Epub 2023 Aug 12. PMID: 37532684. 

Liu, J., Min, S., Kim, D. et al. Pharmacological GLUT3 salvage augments the efficacy of vitamin C-induced TET2 restoration in acute myeloid leukemia. Leukemia 37, 1638–1648 (2023). https://doi.org/10.1038/s41375-023-01954-5 

2022

Choi B, Kang CK, Park S, et al. Single-cell transcriptome analysis reveal distinct gene expression signatures of severe COVID-19 in the presence of clonal hematopoiesis, Exp Mol Med. 2022;ePub 

Song H, Koh Y, Rhee TM, et al, Prediction of incident atherosclerotic cardiovascular disease with polygenic risk of metabolic disease: Analysis of 3 prospective cohort studies in Korea, Atherosclerosis 2022;348:16-24 

Lee C, Lee S, Park E, et al. Transcriptional signatures of the BCL2 family for individualized acute myeloid leukaemia treatment, Genome Med. 2022;14(1):111 

Byun JM, Min CK, Kim K, et al. Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease. J Hematol Oncol. 2022;15(1):150.

Oh TJ, Song H, Koh Y, et al. The presence of clonal hematopoiesis is negatively associated with diabetic peripheral neuropathy in type 2 diabetes. Endocrionl Metab (Seoul). 2022;37(2):243-248

2021

Bolton K, Koh Y, Foote, M et al. Clonal hematopoiesis is associated with risk of severe Covid-19, Nat Comm. 2021;12(1):5975 

Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4. PMID: 34097854. 

2020

Kim D, Koh Y, Yoon SS. Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition. Anticancer Res. 2020;40(3):1395-1403.

Yoon J, Lee S, Sun CH, et al. MED-TMA: A clinical decision support tool for differential diagnosis of TMA with enhanced accuracy using an ensemble method. Thromb Res. 2020;193:154-159.

Ha JH, Lee C, Lee KS, et al. The molecular pathogenesis of Trichilemmal carcinoma. BMC Cancer. 2020;20(1):516.

Lee S, Song S, Yoon SS, et al. Proper Read Filtering Method to Adequately Analyze Whole-Transcriptome Sequencing and RNA Based Immune Repertoire Sequencing Data for Tumor Milieu Research. Cancers (Basel) 2020;12. 

Ku J, Kim R, Kim D, et al. Single-cell analysis of AIMP2 splice variants informs on drug sensitivity and prognosis in hematologic cancer. Commun Biol. 2020;3:630. 

Before 2020

Koh Y, Lee HE, Im SA, et al. VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib. Diagnostic molecular pathology : the American journal of surgical pathology, part B 2011;20:143-7.

Kim I, Koh Y, Yoon SS, et al. Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients. American journal of hematology 2013;88:10-5.

Park S, Koh Y, Jung SH, Chung YJ. Application of array comparative genomic hybridization in chronic myeloid leukemia. Methods in molecular biology 2013;973:55-68.

Koh Y, Lim HY, Ahn JH, et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24:1026-31.

Koh Y, Kim I, Shin DY, et al. Polymorphisms in genes that regulate cyclosporine metabolism affect cyclosporine blood levels and clinical outcomes in patients who receive allogeneic hematopoietic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2012;18:37-43.

Koh Y, Lee HE, Oh DY, et al. The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use. Japanese journal of clinical oncology 2012;42:1020-7.

Koh Y, Kim DW, Kim TM, et al. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6:905-12.

Koh Y, Jang B, Jeon YK, et al. EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma. Japanese journal of clinical oncology 2011;41:548-54.

Koh Y, Kim DY, Park SH, et al. GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridization. Cancer genetics and cytogenetics 2010;203:215-21.

Koh Y, Kim I, Bae JY, et al. Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8. Japanese journal of clinical oncology 2010;40:1037-45.

Koh Y, Lee HR, Song EY, et al. Hypoplastic myelodysplastic syndrome (h-MDS) is a distinctive clinical entity with poorer prognosis and frequent karyotypic and FISH abnormalities compared to aplastic anemia (AA). Leukemia research 2010;34:1344-50.

Koh Y, Kim I, Yoon SS, et al. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib. Annals of hematology 2010;89:725-31.

Koh Y, Jang B, Han SW, et al. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5:320-5.

Koh Y, Bang SM, Lee JH, et al. Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. Annals of hematology 2010;89:201-6.

Koh Y, Kim TM, Jeon YK, et al. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20:1414-9.

Koh Y, Park J, Ahn KS, et al. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway. Annals of hematology 2009;88:1089-97.

Koh Y, Park J, Bae EK, et al. Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype. International journal of hematology 2009;90:1-5.

Koh Y, Jung WJ, Ahn KS, Yoon SS. Establishment of cell lines from both myeloma bone marrow and plasmacytoma: SNU_MM1393_BM and SNU_MM1393_SC from a single patient. BioMed research international 2014;2014:510408.

Koh Y, Lee SY, Kim I, et al. Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients. Cancer chemotherapy and pharmacology 2014;74:653-7.

Park H, Youk J, Kim I, et al. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia. Annals of hematology 2016;95:1777-86.

Youk J, Koh Y, Kim JW, et al. A scientific treatment approach for acute mast cell leukemia: using a strategy based on next-generation sequencing data. Blood research 2016;51:17-22.

Koh Y, Park I, Sun CH, et al. Detection of a Distinctive Genomic Signature in Rhabdoid Glioblastoma, A Rare Disease Entity Identified by Whole Exome Sequencing and Whole Transcriptome Sequencing. Translational oncology 2015;8:279-87.

Lee KW, Koh Y, Kim SB, et al. A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. The oncologist 2015;20:1119-20.

Byun JM, Koh Y, Shin DY, et al. BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors. Haematologica. May 2017;102(5):e187-e190.

Park H, Youk J, Shin DY, et al. Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy. BMC Cancer. 2019;19(1):358.

Song H, Lim Y, Im H, et al. Interpretation of EBV infection in pan-cancer genome considering viral life cycle: LiEB (Life cycle of Epstein-Barr virus). Sci Rep. 2019;9(1):3465.

Shin J, Ko YH, Oh SY, et al. Body Cavity-Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma. Cancer Res Treat. 2019.

Ock CY, Seo H, Kim DY, et al. Discovery of donor genotype associated with long-term survival of patients with hematopoietic stem cell transplantation in refractory acute myeloid leukemia. Leuk Lymphoma. 2019;60(7):1775-1781.

Kim SA, Lee J, Moon JH, et al. Utility of allogeneic hematopoietic stem cell transplantation using international donors in a homogenous ethnic population: question in the era of various alternative donors. Ann Hematol. 2019;98(2):501-510.

Koh Y, Lee JM, Woo GU, et al. FDG PET for Evaluation of Bone Marrow Status in T-Cell Lymphoma. Clin Nucl Med. 2019;44(1):4-10.

Choi M, Jeon YK, Sun CH, et al. RTK-RAS pathway mutation is enriched in myeloid sarcoma. Blood Cancer J. 2018;8(5):43.

Min JW, Koh Y, Kim DY, et al. Identification of Novel Functional Variants of SIN3A and SRSF1 among Somatic Variants in Acute Myeloid Leukemia Patients. Mol Cells. 2018;41(5):465-475.

Park H, Kim D, Kim D et al. Truncation of MYH8 tail in AML: a Novel prognostic marker with increase cell migration and epithelial-mesenchymal transition utilizing RAF/MAPK pathway. Carcinogenesis 2019.

Shin J, Kim D, Kim HL et al. Oncogenic effects of germline variants in lysosomal storage disease genes. Genet Med 2019.

Suh KJ, Shin DY, Kim I et al. Comparison of quality of life and health behaviors in survivors of acute leukemia and the general population. Ann Hematol 2019; 98: 2357-2366.

Byun JM, Song S, Koh Y, Yoon SS, Kim D. The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2-Positive Myeloproliferative Neoplasms. Anticancer Res. 2019;39(11):6273-6282.